TrademarkOpen
Search / United States / 98120597

Heads up: we show every live trademark, plus inactive ones from the last 5 years, in the United States, Singapore, Canada, Australia and France. India is looked up live when you search, so it is not a saved copy of every mark, and it can be busy some days. Data is only as fresh as each country publishes it, and some countries aren’t included yet, so a brand can be registered even if it doesn’t show here. Always check the official record before you use a name. This is not legal advice.

🇺🇸 United States · Service Mark

EAI

Registered
Used for: Clinical diagnostic testing kits comprised of medical diagnostic reagents and assays for testing biopsy and other…
Show more

Clinical diagnostic testing kits comprised of medical diagnostic reagents and assays for testing biopsy and other tissue samples for use in disease detection, namely, breast cancer; clinical diagnostic testing kits comprised of medical diagnostic reagents and assays for breast cancer surveillance, namely, for measuring amounts of genomic and other biomarkers contacted with the reagent, such as estrogen receptor (ER), progesterone receptor (PR) associated biomarkers, and other suitable biomarkers for monitoring breast cancer occurrence, recurrence, response to various chemotherapies, hormone therapies, radiation therapies, or other suitable treatments

Class 5 – Pharmaceuticals & supplements

Status timeline

  1. 10 Aug 2023
    Application filed
    New Application Entered
  2. 8 Apr 2024
    Assigned to an examining attorney
    Assigned To Examiner
  3. 11 Apr 2024
    Office action issued
    Non-Final Action Written
  4. 19 Apr 2024
    Response to office action filed
    Teas Response To Office Action Received
  5. 20 Apr 2024
    Final refusal issued
    Final Refusal Mailed
  6. 12 Sep 2024
    Approved for publication
    Approved For Pub - Principal Register
  7. 22 Oct 2024
    Published for opposition
    Published For Opposition
  8. 3 Dec 2024
    Notice of allowance issued — statement of use required
    Noa Mailed - Sou Required From Applicant
  9. 3 Jun 2025
    Statement of use filed
    Teas Statement Of Use Received
  10. 26 Nov 2025
    Statement of use accepted
    Allowed Principal Register - Sou Accepted
  11. 16 Dec 2025
    Registered on the Principal Register
    Registered-Principal Register
All 32 events
2025-12-16Registered-Principal Register
2025-12-16Notice Of Registration Confirmation Emailed
2025-11-26Allowed Principal Register - Sou Accepted
2025-11-26Notice Of Acceptance Of Statement Of Use E-Mailed
2025-11-22Case Assigned To Intent To Use Paralegal
2025-11-22Statement Of Use Processing Complete
2025-06-03Teas Statement Of Use Received
2025-06-03Use Amendment Filed
2024-12-03Noa Mailed - Sou Required From Applicant
2024-10-22Published For Opposition
2024-10-22Official Gazette Publication Confirmation E-Mailed
2024-10-02Notification Of Notice Of Publication E-Mailed
2024-09-12Assigned To Lie
2024-09-12Correspondence Received In Law Office
2024-09-12Teas/Email Correspondence Entered
2024-09-12Approved For Pub - Principal Register
2024-04-23Teas Request For Reconsideration Received
2024-04-20Final Refusal Mailed
2024-04-20Final Refusal E-Mailed
2024-04-20Notification Of Final Refusal Emailed
2024-04-19Teas Response To Office Action Received
2024-04-19Correspondence Received In Law Office
2024-04-19Teas/Email Correspondence Entered
2024-04-11Non-Final Action Written
2024-04-11Non-Final Action E-Mailed
2024-04-11Notification Of Non-Final Action E-Mailed
2024-04-08Assigned To Examiner
2024-02-12Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
2024-02-12Attorney/Dom.rep.revoked And/Or Appointed
2024-02-12Teas Change Of Correspondence Received
2023-09-06New Application Office Supplied Data Entered
2023-08-10New Application Entered

Goods & services by class

Class 5 Pharmaceuticals & supplements

Clinical diagnostic testing kits comprised of medical diagnostic reagents and assays for testing biopsy and other tissue samples for use in disease detection, namely, breast cancer; clinical diagnostic testing kits comprised of medical diagnostic reagents and assays for breast cancer surveillance, namely, for measuring amounts of genomic and other biomarkers contacted with the reagent, such as estrogen receptor (ER), progesterone receptor (PR) associated biomarkers, and other suitable biomarkers for monitoring breast cancer occurrence, recurrence, response to various chemotherapies, hormone therapies, radiation therapies, or other suitable treatments

First use anywhere 3 Dec 2023 · First use in commerce 3 Dec 2023

Owner details

See the official record for contact details. View official record →

Source & freshness

Source: the official United States trademark register. This record was last updated on 16 Dec 2025; the index was built on 20 Nov 2026 and covers data through 31 Aug 2026. View official record → If the two differ, the official record is correct.